MECT联合二代抗精神病药物治疗精神分裂症的研究进展
Research Progress on MECT Combined with Second-Generation Antipsychotic Drugs in the Treatment of Schizophrenia
DOI: 10.12677/acm.2025.151117, PDF,    科研立项经费支持
作者: 杨 堃：内蒙古医科大学精神卫生学院，内蒙古 呼和浩特；仝利俊*：内蒙古自治区精神卫生中心，内蒙古 呼和浩特
关键词: 无抽搐电休克(MECT)；第二代抗精神病药物；疗效；神经递质；脑源性神经营养因子(BDNF)；MECT； Second-Generation Antipsychotic Drugs； Efficacy； Neurotransmitters； BDNF
摘要: 精神分裂症作为21世纪精神卫生工作的重点，同时作为临床上常见的较为严重的精神障碍之一，一直是临床重点管理及防控的工作内容。精神分裂症的治疗也作为各项研究关注的重点。神经递质以及脑源性神经营养因子的异常作为精神分裂症发病机制中重要环节也常被人关注。本文综述了无抽搐电休克(modified electroconvulsive therapy, MECT)联合二代抗精神病药物治疗精神分裂症的疗效及其对神经递质、脑源性神经营养因子(BDNF)的影响等，从多个方面探讨并总结目前精神分裂症治疗的进展。
Abstract: As the focus of mental health work in the 21st century, and as one of the more serious mental disorders commonly seen in clinical practice, schizophrenia has always been the focus of clinical management, prevention and control. The treatment of schizophrenia has also been the focus of various studies. Abnormalities in neurotransmitters and brain-derived neurotrophic factors are also often considered an important part of the pathogenesis of schizophrenia. This article reviews the efficacy of modified electroconvulsive therapy (MECT) combined with second-generation antipsychotic drugs in the treatment of schizophrenia and its effects on neurotransmitters and brain-derived neurotrophic factor (BDNF). It explores and summarizes the current progress in the treatment of schizophrenia from multiple perspectives.
文章引用：杨堃, 仝利俊. MECT联合二代抗精神病药物治疗精神分裂症的研究进展[J]. 临床医学进展, 2025, 15(1): 871-877. https://doi.org/10.12677/acm.2025.151117

参考文献

[1] Marder, S.R. and Cannon, T.D. (2019) Schizophrenia. New England Journal of Medicine, 381, 1753-1761. [Google Scholar] [CrossRef] [PubMed]
[2] Correll, C.U. and Schooler, N.R. (2020) Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatric Disease and Treatment, 16, 519-534. [Google Scholar] [CrossRef] [PubMed]
[3] 王书华, 阮帅, 张小娟, 等. 精神分裂症住院患者危险行为发生情况及相关因素分析[J]. 医院管理论坛, 2023, 40(4): 14-18.
[4] 黄兢, 唐慧, 伍海姗, 等. 精神分裂症疾病负担及药物治疗现状困境[J]. 中国药物经济学, 2022, 17(11): 16-21, 26.
[5] 褚林娟, 陈彩红, 严丽, 等. 慢性精神分裂症患者血清同型半胱氨酸水平与认知功能的相关性[J]. 临床医学研究与实践, 2024, 9(14): 66-69.
[6] Howes, O.D., Bukala, B.R. and Beck, K. (2023) Schizophrenia: From Neurochemistry to Circuits, Symptoms and Treatments. Nature Reviews Neurology, 20, 22-35. [Google Scholar] [CrossRef] [PubMed]
[7] 马爱清, 孙建平, 庞檬佼. MECT联合第二代抗精神病药治疗精神分裂症的效果及对脑电图、认知功能的影响[J]. 中外医学研究, 2022, 20(31): 62-66.
[8] 王艳, 任秀, 张玉环. 无抽搐电休克治疗对青年精神分裂症患者认知功能及短时记忆损伤的影响研究[J]. 心理月刊, 2024, 19(13): 115-117, 129.
[9] Yu, W., Huang, J., He, S., Zhang, L., Shen, Y. and Li, H. (2021) Safety and Related Factors of Treatment with Long-Term Atypical Antipsychotic in Chinese Patients with Schizophrenia: Observational Study. General Psychiatry, 34, e100289. [Google Scholar] [CrossRef] [PubMed]
[10] Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., et al. (2013) Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. The Lancet, 382, 951-962. [Google Scholar] [CrossRef] [PubMed]
[11] De Fazio, P., Gaetano, R., Caroleo, M., Cerminara, G., Maida, F., Bruno, A., et al. (2015) Rare and Very Rare Adverse Effects of Clozapine. Neuropsychiatric Disease and Treatment, 11, 1995-2003. [Google Scholar] [CrossRef] [PubMed]
[12] Azmanova, M., Pitto-Barry, A. and Barry, N.P.E. (2018) Schizophrenia: Synthetic Strategies and Recent Advances in Drug Design. MedChemComm, 9, 759-782. [Google Scholar] [CrossRef] [PubMed]
[13] Mohammed, W. and Al Naeem, W. (2022) Prevalence and Management of Metabolic Syndrome in Adult Psychiatric Patients Receiving Second-Generation Antipsychotics at Sheikh Khalifa Medical City. Cureus, 14, e22021. [Google Scholar] [CrossRef] [PubMed]
[14] Wagner, E., Siafis, S., Fernando, P., Falkai, P., Honer, W.G., Röh, A., et al. (2021) Efficacy and Safety of Clozapine in Psychotic Disorders—A Systematic Quantitative Meta-Review. Translational Psychiatry, 11, Article No. 487. [Google Scholar] [CrossRef] [PubMed]
[15] 钱科佳, 陈婷, 赵楠, 等. 抗精神病药物联合无抽搐电休克治疗精神分裂症伴顽固性幻听的临床疗效[J]. 心理月刊, 2022, 17(21): 55-57.
[16] 张红, 于滨, 张国玲, 等. 无抽搐电休克治疗对精神分裂症患者短时记忆损伤及恢复周期的影响研究[J]. 陕西医学杂志, 2018, 47(2): 162-164.
[17] 焦雪影, 苏珍. 阿立哌唑联合无抽搐电休克治疗精神分裂症的效果及安全性分析[J]. 淮海医药, 2024, 42(4): 403-407.
[18] Purohith, A.N., Chatorikar, S.A., Praharaj, S.K., Bhandary, R.P. and Sharma, P.S.V.N. (2022) Efficacy and Safety of Maintenance Electroconvulsive Therapy (M-ECT) in Treatment-Resistant Schizophrenia: A Case Series. Asian Journal of Psychiatry, 73, Article ID: 103132. [Google Scholar] [CrossRef] [PubMed]
[19] Mu, X., Xu, J., Lin, P., Luo, Y., Zhu, Y., Shi, Y., et al. (2022) A Case Report of Leukocytosis during Modified Electroconvulsive Therapy of Paranoid Personality Disorder. Frontiers in Psychiatry, 13, Article 899847. [Google Scholar] [CrossRef] [PubMed]
[20] Ahmadvand, A., Bagherzadeh Shahidi, S., Talari, H., Sadat Ghoreishi, F. and Abbas Mousavi, G. (2017) Morphology of the Corpus Callosum and Schizophrenia: A Case-Control Study in Kashan, Iran. Electronic Physician, 9, 5478-5486. [Google Scholar] [CrossRef] [PubMed]
[21] 孟强. 阿立哌唑联合MECT治疗男性精神分裂症的效果及对记忆和执行功能影响[J]. 罕少疾病杂志, 2024, 31(3): 24-26.
[22] 朱虹, 宋婷. MECT联合药物治疗精神分裂症患者的效果及对血清BDNF、GFAP、PRL水平的影响[J]. 中国医学创新, 2024, 21(19): 1-6.
[23] Daskalakis, A.A., Paric, A., Ravindran, N. and Ravindran, A. (2024) Evaluating the Use of Electroconvulsive Therapy in Low-Middle Income Countries: A Narrative Review. Asian Journal of Psychiatry, 91, Article ID: 103856. [Google Scholar] [CrossRef] [PubMed]
[24] Howes, O.D., Fusar-Poli, P., Bloomfield, M., Selvaraj, S. and McGuire, P. (2012) From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments. Current Pharmaceutical Design, 18, 459-465. [Google Scholar] [CrossRef] [PubMed]
[25] Zahid, U., McCutcheon, R.A., Borgan, F., Jauhar, S., Pepper, F., Nour, M.M., et al. (2022) The Effect of Antipsychotics on Glutamate Levels in the Anterior Cingulate Cortex and Clinical Response: A 1H-MRS Study in First-Episode Psychosis Patients. Frontiers in Psychiatry, 13, Article 967941. [Google Scholar] [CrossRef] [PubMed]
[26] Richetto, J., Labouesse, M.A., Poe, M.M., Cook, J.M., Grace, A.A., Riva, M.A., et al. (2015) Behavioral Effects of the Benzodiazepine-Positive Allosteric Modulator SH-053-2’F-S-CH3 in an Immune-Mediated Neurodevelopmental Disruption Model. International Journal of Neuropsychopharmacology, 18, pyu055. [Google Scholar] [CrossRef] [PubMed]
[27] Tsapakis, E.M., Diakaki, K., Miliaras, A. and Fountoulakis, K.N. (2023) Novel Compounds in the Treatment of Schizophrenia—A Selective Review. Brain Sciences, 13, Article 1193. [Google Scholar] [CrossRef] [PubMed]
[28] Li, P., L. Snyder, G. and E. Vanover, K. (2016) Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Current Topics in Medicinal Chemistry, 16, 3385-3403. [Google Scholar] [CrossRef] [PubMed]
[29] Amato, D., Kruyer, A., Samaha, A. and Heinz, A. (2019) Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. Frontiers in Psychiatry, 10, Article 314. [Google Scholar] [CrossRef] [PubMed]
[30] 范桂红, 何俊, 庞高峰, 等. 无抽搐电休克疗法对精神分裂症患者的治疗效果和脑内及不同脑区神经递质水平的影响研究[J]. 中国全科医学, 2022, 25(3): 325-330.
[31] Nieto, R., Kukuljan, M. and Silva, H. (2013) BDNF and Schizophrenia: From Neurodevelopment to Neuronal Plasticity, Learning, and Memory. Frontiers in Psychiatry, 4, Article 45. [Google Scholar] [CrossRef] [PubMed]
[32] Nurjono, M., Lee, J. and Chong, S. (2012) A Review of Brain-Derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia. Clinical Psychopharmacology and Neuroscience, 10, 61-70. [Google Scholar] [CrossRef] [PubMed]
[33] 王轶虎, 陶百平, 李素荣, 等. 第一、二代抗精神病药物对首发精神分裂症患者脑源性神经营养因子及认知功能的相关性研究[J]. 中国现代医生, 2020, 58(20): 28-31.
[34] de Bartolomeis, A., Buonaguro, E.F., Latte, G., Rossi, R., Marmo, F., Iasevoli, F., et al. (2017) Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes. Frontiers in Behavioral Neuroscience, 11, Article 240. [Google Scholar] [CrossRef] [PubMed]
[35] Bazzari, A.H. and Bazzari, F.H. (2022) BDNF Therapeutic Mechanisms in Neuropsychiatric Disorders. International Journal of Molecular Sciences, 23, Article 8417. [Google Scholar] [CrossRef] [PubMed]

为你推荐